SCHEMBL14009128

SCHEMBL14009128

O=C(NCC1CCCCC1)c1ccc(C(=O)Nc2ccc(-n3cncn3)cc2)s1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 2/20 0.50
▸ HDAC4 P56524 2/20 0.50
▸ HDAC6 Q9UBN7 2/20 0.50
▸ HDAC1 Q13547 1/20 0.50
▸ S1PR1 P21453 2/20 0.45
▸ CTSL P07711 1/20 0.44
▸ CTSS P25774 1/20 0.44
▸ CTSK P43235 1/20 0.44
▸ F10 P00742 1/20 0.42
▸ NAMPT P43490 6/20 0.42
▸ CCR3 P51677 1/20 0.42
▸ EPHX1 P07099 2/20 0.40
▸ SMYD3 Q9H7B4 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ CNR1 P21554 1/20 0.39
▸ ROCK1 Q13464 1/20 0.39
▸ EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14009174 0.87 NAMPT (0.47) HDAC3HDAC4HDAC6HDAC1S1PR1
SCHEMBL14009129 0.85 KMT2A (0.50) NAMPT
SCHEMBL14009120 0.85 KMT2A (0.50) NAMPT
SCHEMBL14009119 0.85 SMYD3 (0.48) S1PR1CTSLCTSSCTSKCCR3
SCHEMBL14009095 0.83 SMYD3 (0.49) S1PR1CTSLCTSSCTSKNAMPT
SCHEMBL14009091 0.81 SMYD3 (0.49) S1PR1NAMPTCCR3SMYD3NPC1
SCHEMBL14009160 0.81 SMYD3 (0.43) S1PR1CTSLCTSSCTSKNAMPT
SCHEMBL14009195 0.81 NAMPT (0.45) NAMPTNPC1RAB9ACNR1EPHX2
SCHEMBL14009108 0.81 SMYD3 (0.53) S1PR1CCR3SMYD3NPC1RAB9A
SCHEMBL14009039 0.80 S1PR1 (0.43) S1PR1CTSLCTSSCTSKRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed
WO-2007022258-A1 NOVEL HIGH AFFINITY THIOPHENE-BASED AND FURAN-BASED KINASE LIGANDS SCHERING CORPORATION (US) 2007-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands CDKL2, CDK2, CDKL1 HDAC3 2248/4885HDAC4 1484/4885HDAC6 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback